Target intelligence / Profile preview

MicroRNA-181a target messenger RNAs (miR-181a targets) (miR-181a targets)

Target
miR-181a targets
Molecular classification
Messenger RNA, Nucleic acid
01

Overview

MicroRNA-181a (miR-181a) target messenger RNAs (mRNAs) represent a diverse group of transcripts post-transcriptionally regulated by the miR-181a family, which plays a critical role in modulating cellular processes such as immune cell development, apoptosis, and proliferation (Indrieri et al., 2020, Int J Mol Sci). By binding to the 3' untranslated regions (UTRs) of specific mRNAs, miR-181a functions as a post-transcriptional regulator, typically leading to translational repression or mRNA degradation (Ouyang et al., 2012, J Cereb Blood Flow Metab). Key validated targets include pro-survival genes like BCL2 and MCL1, as well as signaling regulators such as SHP-2 and DUSP6, which influence T-cell receptor sensitivity and the MAPK/ERK pathway (Li et al., 2007, Nature). In oncology, the miR-181a/mRNA axis is frequently dysregulated; for instance, its downregulation can lead to the overexpression of anti-apoptotic proteins in certain leukemias, while its upregulation may drive progression in other solid tumors (Zhu et al., 2012, Blood). Therapeutic strategies involve using miR-181a mimics to restore regulation of these target mRNAs or antagomirs to block miR-181a activity, thereby modulating the expression of the entire target network to treat cancer or inflammatory diseases.

Other names
hsa-miR-181a-5p targetsmiR-181a-3p targetsMicroRNA-181a regulated transcriptsmiR-181a-5p/mRNA axis
02

Mechanism of action

MicroRNA-181a binds to the 3' untranslated region (UTR) of target mRNAs via seed sequence complementarity, resulting in the recruitment of the RNA-induced silencing complex (RISC), which mediates translational inhibition or mRNA decay (Ouyang et al., 2012, J Cereb Blood Flow Metab).

03

Biological functions

Apoptosis regulationT-cell developmentCell differentiationSignal transductionCell proliferationImmune response modulation
04

Disease associations

CancerHematologic malignanciesCardiovascular diseaseNeurodegenerative diseaseInflammation
05

Safety considerations

Off-target effects on non-intended mRNAsInnate immune activation by exogenous RNATissue-specific delivery challengesPotential for oncogenic or tumor-suppressive dual roles depending on context
06

Interacting drugs

miR-181a mimics

2 more in the full profile.

07

Biomarkers

miR-181a expression levelsBCL2 protein levelsMCL1 protein levelsDUSP6 expressionT-cell receptor (TCR) signaling sensitivity

Beyond the preview

Go deeper on MicroRNA-181a target messenger RNAs (miR-181a targets) (miR-181a targets).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MicroRNA-181a target messenger RNAs (miR-181a targets) (miR-181a targets).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call